Clinical
Explore Aiforia’s comprehensive portfolio of high-performance AI solutions, engineered for both clinical and preclinical applications. Aiforia’s solutions aim to enhance the speed, accuracy, and consistency of analyzing large and complex medical images, especially in pathology.
Learn moreResearch
Aiforia’s research solutions offer fully automated study-centric workflows and pathology image analysis applications that cater to all research areas. Empowered by robust AI capabilities, pathologists and scientists can make discoveries while saving time by automating repetitive tasks – also within the framework of GLP. Aiforia’s solutions can be integrated with any existing laboratory infrastructure to enjoy the full benefits of a digitized workflow.
Learn moreAiforia® Create is the most versatile tool for developing deep learning AI models for image analysis in digital pathology. Its cloud-based, collaborative working environment allows multiple users to work together in real time, anywhere in the world. Praised for its intuitive user interface, it allows users a fast start, even without any prior AI experience.Learn more >
Learn moreExplore Aiforia’s comprehensive portfolio of high-performance AI solutions, engineered for both clinical and preclinical applications. Aiforia’s solutions aim to enhance the speed, accuracy, and consistency of analyzing large and complex medical images, especially in pathology.
Learn moreAI development tool
Aiforia® Create is the most versatile tool for developing deep learning AI models for image analysis in digital pathology. Its cloud-based, collaborative working environment allows multiple users to work together in real time, anywhere in the world. Praised for its intuitive user interface, it allows users a fast start, even without any prior AI experience.
Learn moreResources
Explore some of our latest publications showcasing the discoveries enabled by the Aiforia® Platform.
Learn moreAiforia's insights and resources for AI in pathology. View some of our content pieces from the world of AI.
Learn moreStay updated with Aiforia’s recent announcements. Explore our latest news, updates and announcements.
Learn moreCompany
Find out more about shareholder matters, investment discussions, and financial-related information.
Learn moreAiforia's mission is to transform pathology image analysis with AI, enabling better care for each patient. To succeed, we need our trusted partners. Explore Aiforia’s partner network.
Learn moreExperience our AI solutions firsthand. Explore the list of conferences where you can connect with Aiforia’s team live and book a time to discover the future of AI-powered image analysis.
Learn moreOur mission is to transform pathology image analysis with AI, enabling better care for each patient. Find out more about job openings, thesis opportunities, or submitting applications.
Learn moreAiforia Technologies holds information security to the highest standard. We hold several, globally relevant quality and security certifications, so you can be sure your sensitive information is safe.
Learn moreClinical
Clinical Solutions
AI solutions portfolio
Research
AI development tool
Aiforia® Create
Resources
Company
About us
Investors
Partners
Media
Events
Careers
Quality and security
Preeclampsia, a hypertensive pregnancy disorder, is a major cause of maternal and perinatal mortality and morbidity.1 Satu Wedenoja, MD, PhD, a Specialist in Obstetrics and Gynecology at Helsinki University Hospital, and her team studied the link between preeclampsia, fetal human leukocyte antigen G (HLA-G), and other genes regulating maternal immune responses.
The team decided to use Aiforia software "to confirm earlier findings of HLA-G down-regulation in the preeclamptic placenta and show that the observed low level of expression is not related to the number of trophoblasts in the samples", as Satu explains.
Two convolutional neural network-based algorithms were trained using Aiforia® Create to identify anti-CK7 and anti-HLA-G immunostained tissue areas separately. Each algorithm consists of two algorithms in sequence, the first segmenting the extravillous tissue areas and the second identifying trophoblasts that exhibit a strong HLA-G or CK7 expression, respectively.
Read Satu's interview below, and read their full publication here.
"Aiforia was excellent in providing HLA-G/CK7 ratios for protein expression, and we were able to show a nice correlation between HLA-G/CK7 protein and RNA expression levels. With Aiforia analysis, we obtained novel data by demonstrating that HLA-G protein down-regulation in the preeclamptic placentas was not explained by the lower number of trophoblasts in the placental samples.
Quantitative analysis of protein expression also helped us demonstrate the association between HLA-G protein expression and fetal sex, which supported the overall conclusions of our study."

"Aiforia allowed us to count the number of HLA-G positive cells on the placental tissue sections. Moreover, we were able to calculate the proportion of HLA-G positive cells in comparison with all placental epithelial cells on the slides, stained by the trophoblast marker CK7."
Read more case studies:
References
Wedenoja, S. et al. (2020, September). Fetal HLA-G mediated immune tolerance and interferon response in preeclampsia. eBioMedicine, 59. https://doi.org/10.1016/j.ebiom.2020.102872